VSTM 241220 6.00C (VSTM241220C6000) Stock Options, News & Quotes

US OptionsDetailed Quotes

VSTM241220C6000

Watchlist

0.23
+0.13+130.00%

15min DelayClose Nov 29 13:00 ET

0.23High0.14Low

Intraday

5D
Daily

News

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
BusinesswireNov 26 07:00 ET
Verastem Inc. Reports Increased Operating Expenses and Net Loss
TipRanksNov 21 22:54 ET
Byondis Appoints Louis Denis, M.D., as Chief Medical Officer
BusinesswireNov 19 01:11 ET
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
Moomoo NewsNov 7 07:31 ET · Ratings
A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
Moomoo NewsNov 7 07:31 ET · Ratings
Verastem Price Target Lowered to $14 From $20 at Alliance Global Partners
TipRanksNov 7 07:06 ET

Comments

Tonyco

Nov 29 13:05

$Verastem (VSTM.US)$
If you had bought on 10/31 my last comment, you'd be up 30% now, grats

Tonyco

Oct 31 22:49

$Verastem (VSTM.US)$
Pretty damn good run so far. I only managed to hop on in Sept.

Jaguar8

Oct 31 15:01

NEWS

$Verastem (VSTM.US)$
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...

Webcast today. Possible PR Monday.

$Verastem (VSTM.US)$